ASIA RAY (01993) Announces Profit Expected to Reach Approximately RMB 14.6 million in the Mid-Term, Turning Loss into Profit on a Year-on-Year Basis.
Yashowei (01993) announces that it expects to achieve a net profit of approximately RMB... for the six months ending on June 30, 2025.
ASIARAY (01993) announced that it is expected to achieve a net profit of approximately RMB 14.6 million for the six months ending on June 30, 2025, while it incurred a net loss of approximately RMB 7.6 million for the six months ending on June 30, 2024. The board of directors believes that the turnaround from net loss to net profit is mainly due to the following factors compared to the previous period: (i) improvement in operating performance after terminating underperforming projects; (ii) reduction in royalties for certain projects; and (iii) improvement in cost control strategies.
Related Articles

Zhongtai: Does the upward trend in coal stocks represent the resurgence of "inflation trades"?

MOON INC (01723) intends to subscribe for a 2.97% stake in Asia Strategy Partners LLC for $1.2 million.

AB&B BIO-TECH-B (02627): Recombinant respiratory syncytial virus vaccine (CHO cells) adjuvant IND approved by China CDE and US FDA.
Zhongtai: Does the upward trend in coal stocks represent the resurgence of "inflation trades"?

MOON INC (01723) intends to subscribe for a 2.97% stake in Asia Strategy Partners LLC for $1.2 million.

AB&B BIO-TECH-B (02627): Recombinant respiratory syncytial virus vaccine (CHO cells) adjuvant IND approved by China CDE and US FDA.

RECOMMEND

Trump Administration Explores Government Equity Investment in Intel; Shares Soar Nearly 9%
15/08/2025

Inflation “Off the Charts”: U.S. July Producer Prices Surge 0.9% Month-on-Month, 3.3% Year-on-Year
15/08/2025

World Humanoid Robot Games Debut with Competitions in Soccer, Combat, Dance, and More
15/08/2025